Therapeutics
Drug-class and individual-agent evidence: GLP-1 receptor agonists, SGLT2 inhibitors, and the major trials behind semaglutide, tirzepatide, and related therapies.
Study Shows Tirzepatide Improves Heart Failure Outcomes and Quality of Life in Obese Patients
In patients with heart failure with preserved ejection fraction (HFpEF) and obesity, tirzepatide significantly reduced the composite risk of cardiovascular death or worsening heart failure and improved health status compared to placebo, though it was associated with higher gastrointestinal side effects.
Liraglutide’s Efficacy in Children Aged 6-12
In children aged 6 to
Tirzepatide for Obstructive Sleep Apnea: Phase 3 Trial Shows 59% Reduction in AHI
In adults with moderate-to-severe obstructive sleep apnoea (OSA) and obesity, tirzepatide significantly reduced the apnea-hypopnea index (AHI) and body weight compared to placebo, with notable improvements in sleep-related outcomes and cardiovascular risk factors, albeit with increased gastrointestinal side effects.
Once-Weekly Semaglutide Shows Promise in Reducing Weight and Pain for Patients with Obesity-Related Knee Osteoarthritis: STEP 9 Trial Findings
In patients with obesity and knee osteoarthritis, once-weekly semaglutide (2.4 mg) significantly reduced body weight and pain compared to placebo, though it was associated with gastrointestinal side effects.
Efficacy and Safety of Oral Semaglutide as an Add-On to Metformin Therapy in Type 2 Diabetes: Insights from the PIONEER 3 Trial
In adults with type 2 diabetes inadequately controlled with metformin (alone or with sulfonylurea), oral semaglutide (7 mg and 14 mg) significantly reduced HbA1c and body weight compared to sitagliptin over 26 weeks, while the 3 mg dose showed no significant benefit.
Efficacy and Safety of Adding Semaglutide to SGLT-2 Inhibitors in Type 2 Diabetes Management: A Review of the SUSTAIN 9 Trial
In patients with inadequately controlled type 2 diabetes on SGLT-2 inhibitors, adding semaglutide significantly improved HbA1c and reduced body weight compared to placebo, though it was associated with an increased frequency of gastrointestinal side effects.
Oral Semaglutide Proven Cardiovascular Safe for High-Risk Type 2 Diabetes Patients
In patients with type 2 diabetes at high cardiovascular (CV) risk, oral semaglutide demonstrated non-inferior cardiovascular safety to placebo, showing no significant increase in major adverse cardiovascular events (MACE), which included cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.